Azilsartan medomoxil is a relatively new addition to the class of ARBs approved for the indication of essential hypertension [14,15]. Evidence generated in the preclinical studies suggests that like telmisartan, azilsartan too improves insulin sensitivity in different animal models by affecting PPAR-γ and TNF-α and, hence, can be expected to promote insulin sensitivity in human subjects [16,17]. However, there is a paucity of data available for the head-on comparison between the effect of telmisartan and azilsartan on insulin resistance and metabolic biomarkers. The gene discussed is INS; the disease is essential hypertension.